IDEXX Laboratories, Inc. $IDXX Shares Sold by Westwind Capital

Westwind Capital trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,141 shares of the company’s stock after selling 14,604 shares during the period. IDEXX Laboratories makes up approximately 4.1% of Westwind Capital’s portfolio, making the stock its 9th biggest position. Westwind Capital’s holdings in IDEXX Laboratories were worth $19,896,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in shares of IDEXX Laboratories by 156.2% during the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after purchasing an additional 884,808 shares during the period. Generation Investment Management LLP bought a new stake in shares of IDEXX Laboratories during the second quarter worth about $304,277,000. Select Equity Group L.P. acquired a new stake in shares of IDEXX Laboratories in the 1st quarter worth about $194,834,000. Norges Bank acquired a new position in IDEXX Laboratories during the 2nd quarter valued at about $221,955,000. Finally, Durable Capital Partners LP purchased a new stake in shares of IDEXX Laboratories in the first quarter worth approximately $153,180,000. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on IDXX shares. Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Barclays assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They issued an “overweight” rating and a $850.00 price objective for the company. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a report on Monday, November 3rd. Finally, UBS Group boosted their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 0.3%

Shares of IDXX stock opened at $702.12 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. The firm has a market cap of $56.06 billion, a P/E ratio of 55.68, a PEG ratio of 4.18 and a beta of 1.67. The company has a 50 day moving average of $691.74 and a 200-day moving average of $628.25. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period last year, the business posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.